Portage Biotech Inc. (PRTG)
NASDAQ: PRTG · Real-Time Price · USD
4.617
+0.047 (1.05%)
Nov 21, 2024, 1:46 PM EST - Market open
Portage Biotech Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Portage Biotech.
Analyst Consensus: Hold
Analyst Ratings
According to 1 stock analyst, the rating for PRTG is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.
Recommendation Trends
Rating | Aug '23 | Sep '23 | Oct '23 | Nov '23 | Dec '23 | Jan '24 |
---|---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
Buy | 2 | 2 | 2 | 2 | 2 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 3 | 3 | 3 | 3 | 3 | 1 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jan 8, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $180 → $120 | Strong Buy | Maintains | $180 → $120 | +2,498.92% | Nov 29, 2023 |
Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $220 | Buy | Reiterates | $220 | +4,664.69% | Sep 7, 2023 |
Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $220 | Buy | Reiterates | $220 | +4,664.69% | Aug 31, 2023 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $420 → $180 | Strong Buy | Maintains | $420 → $180 | +3,798.38% | Aug 2, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.53
from -77.90
EPS Next Year
-0.53
from -0.53
Revenue Forecast
Revenue | 2024 | 2025 |
---|---|---|
High | n/a | n/a |
Avg | n/a | n/a |
Low | n/a | n/a |
Revenue Growth
Revenue Growth | 2024 | 2025 |
---|---|---|
High | - | - |
Avg | - | - |
Low | - | - |
EPS Forecast
EPS | 2024 | 2025 |
---|---|---|
High | -0.55 | -0.55 |
Avg | -0.53 | -0.53 |
Low | -0.51 | -0.51 |
EPS Growth
EPS Growth | 2024 | 2025 |
---|---|---|
High | - | - |
Avg | - | - |
Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.